Hostname: page-component-745bb68f8f-g4j75 Total loading time: 0 Render date: 2025-02-11T15:15:58.556Z Has data issue: false hasContentIssue false
  • English
  • Français

Isolated primary non-Hodgkin’s malignant lymphoma of the larynx

Published online by Cambridge University Press:  08 March 2006

Andrea Luigi Cavalot ,
Giuliana Preti ,
Nicola Vione ,
Giuseppe Nazionale ,
Francesca Palonta  and
Gian Luca Fadda
Andrea Luigi Cavalot
Affiliation:
Department of Physiology, Second Chair of ENT, University of Turin, Italy.
Giuliana Preti
Affiliation:
Department of Physiology, Second Chair of ENT, University of Turin, Italy.
Nicola Vione
Affiliation:
Department of Physiology, Second Chair of ENT, University of Turin, Italy.
Giuseppe Nazionale
Affiliation:
Department of Physiology, Second Chair of ENT, University of Turin, Italy.
Francesca Palonta
Affiliation:
Department of Physiology, Second Chair of ENT, University of Turin, Italy.
Gian Luca Fadda
Affiliation:
Department of Physiology, Second Chair of ENT, University of Turin, Italy.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We report a case of glottic primary laryngeal lymphoma. Although the head and neck region is a frequent site of origin of extranodal non-Hodgkin’s lymphomas, laryngeal involvement is exceptional. Including this case, about 90 primary laryngeal lymphomas have been reported in the literature. Microscopic study showed a diffuse malignant lymphoma of high-grade malignancy (WF sub-division H). A diffuse, large, B-cell-type NHL was diagnosed histopathologically.

The patient was treated with combination chemotherapy, including cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP), which resulted in complete clinical remission after two courses. Four courses of combination chemotherapy were subsequently performed, making a total of six courses of combination chemotherapy. No recurrence has been observed during the 16-month follow-up period.

Keywords

LymphomaLarynx
Type
Research Article
Information
The Journal of Laryngology & Otology , Volume 115 , Issue 4 , April 2001 , pp. 324 - 326
Copyright
© Royal Society of Medicine Press Limited 2001